در هنگام جستجو کلمه در قسمت عنوان میتوانید کلمات مورد جستجو را با کاراکتر (-) جدا کنید.
کاربرد نوع شرط:
- جایگاه : پژوهشی
- مجله: Asian Pacific Journal of Cancer Prevention
- نوع مقاله: Journal Article
- کلمات کلیدی: Thrombocytosis,primary myelofibrosis,myeloproliferative disorders
- چکیده:
- چکیده انگلیسی: Primary Myelofibrosis is a BCR-ABL negative myeloproliferative neoplasm with a variety of hematological
presentations, including thrombosis, bleeding diathesis and marrow fibrosis. It is estimated to have an incidence of
1.5 per 100,000 people each year. Although JAK2 or MPL mutations are seen in PMF, several other mutations have
recently been documented, including mutations in CALR, epigenetic regulators like TET, ASXL1, and 13q deletions.
The identification of these mutations has improved the ability to develop novel treatment options. These include JAK
inhibitors like ruxolitinib, heat shock protein-90 inhibitors like ganetespib, histone deacetylase inhibitors including
panobinostat, pracinostat, vorinostat and givinostat, hypomethylating agents like decitabine, hedgehog inhibitors like
glasdegib, PI3K, AKT and mTOR inhibitors like everolimus as well as telomerase inhibitors like imtelstat. Research
on novel therapeutic options is being actively pursued in order to expand treatment options for primary myelofibrosis
however currently, there is no curative therapy other than allogenic hematopoietic stem cell transplantation (ASCT)
which is possible in select patients.- انتشار مقاله: 22-05-1397
- نویسندگان: Jaleed Ahmed Gilani,Muhammad Areeb Ashfaq,Armaghan-e-Rehman Mansoor,Adnan Abdul Jabbar,Tariq Siddiqui,Maliha Khan
- مشاهده